Adicet Bio, Inc. Common Stock (ACET)
PHARMACEUTICAL PREPARATIONS
Adicet Bio, Inc. Common Stock (ACET) is listed on Nasdaq, where it has traded since September 16, 2020.
- Listed On
- Nasdaq
- Listed Since
- September 16, 2020
- Employees
- 102
- Market Cap
- $36M
About Adicet Bio, Inc. Common Stock
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 54 institutions reported holding ACET, with 6.1 million shares worth $52.8 million in aggregate. The largest reported holder was RA Capital Management, with 932,624 shares worth $8.1 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management | 932,624 | $8M | Reduced 21.14% |
| Orbimed Advisors | 844,787 | $7M | Reduced 17.82% |
| Franklin Resources | 626,571 | $5M | Unchanged |
| Citadel Advisors | 432,738 | $4M | Added 13.33% |
| Vanguard | 399,119 | $3M | Added 1.8% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ACET?
Adicet Bio, Inc. Common Stock (ACET) is listed on Nasdaq, where it has traded since September 16, 2020.
Who are the largest institutional holders of ACET?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ACET were RA Capital Management, Orbimed Advisors and Franklin Resources.
How many institutions own ACET?
54 institutions reported a position in ACET for the quarter ended June 30, 2026, worth $52.8 million in total.
Did institutions buy or sell ACET last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ACET.
Every reported institutional holder, plus insider and congressional trades in ACET, on SentiSense.